US distributes monoclonal antibodies this week, but not COVID-19 pills – Precision vaccinations
The US HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) announced today that it is distributing 225,590 monoclonal antibody treatments, but no COVID-19 oral antivirals this week.
There are four mAbs cleared but not approved by the US FDA to treat certain patients as of January 17, 2022.
The ASPR distribution list shows the total number of patient courses that have been distributed across the country.
- Bamlanivimab/ etesevimab = 44,550
- Evusheld = 73,752
- REGEN-COV = 55,224
- Sotrovimab = 52,064
Additionally, this week’s national ASPR allocation indicates that (0) COVID-19 oral antivirals were distributed.
During the week of January 11, 99,960 Pfizer Paxlovid and 399,920 Merck Molnupiravir were awarded to US states, territories and agencies. Both Paxlovid and Molnupiravir are cleared by the US FDA.
Regarding the efficacy of these mAbs and antivirals, the US NIH OpenData portal reported on January 17, 2022 in vitro therapeutic activity against the Omicron variant.
As of 2:00 p.m. CT on January 17, NIH data indicates that sotrovimab may offer the best protection against the SARS-COV-2 virus variant known as Omicron.
As the prevalence of variants changes and new therapies become available, the US government is making tools and resources available to help prescribers make clinical decisions. For example, the US HHS released an updated “Therapeutic Clinical Implementation Guide” on December 29, 2021.
The latest news and information on monoclonal antibodies is published on this webpage.
PrecisionVaccinations publishes evidence-based vaccine information based on research.